fbpx

Development of next-generation leukaemia treatment was kick-started by an ACRF grant

Extracts from St Vincent’s Institute Media Release, 26th of August 2009.

Recent work at St Vincent’s Institute (SVI) using the Australian Synchrotron may help in the development of next-generation drugs to treat major diseases such as leukaemia.

Professor Michael Parker’s team at SVI has used the Australian Synchrotron to visualize a protein called the GM-CSF receptor. Abnormal signalling through this family of receptors is thought to be involved in certain types of leukaemia.

“More detailed knowledge of the shape of the receptor and its function may help us to design new and potentially more effective drugs to target leukaemia,” said Professor Parker.

Continue reading “Development of next-generation leukaemia treatment was kick-started by an ACRF grant”